Next generation biopharmaceuticals with targeted brain transport - from prototypes to candidate drugs
| Reference number | |
| Coordinator | Key2Brain AB |
| Funding from Vinnova | SEK 900 000 |
| Project duration | May 2023 - May 2024 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Startups step 2 spring 2023 |
Important results from the project
The goal of the project, to prepare our targeting technology for clinical phase together with collaborators, has been achieved in several ways. We have validated the functionality and strength of our technology and our competence, as well as protected intellectual property rights, which is a prerequisite for further work.
Expected long term effects
As a result of the project, our technology has been validated to create future drug candidates. Our technology has proven to be versatile and suitable as part of new drugs with maintained function, as well as translationally adapted for humans. Our team has grown and we continue to expand both on a staff level and in partners and revenue.
Approach and implementation
We have systematically worked our way through various work packages that have driven the project to completion. By tackling several issues in parallel, we have been able to accelerate our development towards clinical application. New methods have been established and new intellectual property rights have been built up.